The charity of former New York City Mayor
Michael Bloomberg said Friday it's giving $50 million to fight the
opioid crisis in the United States.
Bloomberg Philanthropies said the money is being given through a
partnership with Vital Strategies, The Pew Charitable Trusts, Johns
Hopkins University and the U.S. Centers for Disease Control and
Prevention.
The alliance will focus on identifying approaches and gaps in current
treatment and prevention programs, and work closely with officials and
experts to evaluate and track the impact of new interventions.
The announcement Friday was made at the inaugural Bloomberg American
Health Summit in Washington, D.C., which seeks to spur innovation among
healthcare innovators for some of the nation's greatest health
challenges.
"We are experiencing a national crisis: For the first time since World
War I, life expectancy in the U.S. has declined over the past three
years -- and opioids are a big reason why," Bloomberg, the city's mayor
between 2002 and 2013 and new Democrat, said.
"We cannot sit by and allow this alarming trend to continue -- not when
so many Americans are being killed in what should be the prime of their
lives. Today we are launching a groundbreaking new partnership."
The CDC said Thursday more than 72,000 Americans died from drug
overdoses last year using illicit and legal opioids -- a two-fold
increase over the last decade. Its studies said life expectancy in the
United States fell from 76.2 in 2016 to 76.1 in 2017, partly due to the
highly-addictive opioids.
"That is the highest drug death toll in American history -- by far,"
Acting Attorney General Matthew Whitaker told law enforcement officials
in northern Kentucky Friday. "That's roughly the size of the population
of Canton, Ohio, dead in just one year from drug overdoses.
"This is a daunting situation."
Whitaker said the federal government's new efforts to fight synthetic
fentanyl trafficking -- particularly from China -- have been working.
The Justice Department and U.S. Drug Enforcement Administration called
in August for a reduction next year in the manufacture of the controlled
substances.
"This significant drop in prescriptions by doctors and DEA's production
quota adjustment will continue to reduce the amount of drugs available
for illicit diversion and abuse while ensuring that patients will
continue to have access to proper medicine," DEA acting administrator
Uttam Dhillon said in a statement.
Comments
Post a Comment